Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome: Current Status of Clinical Applications and Future Directions
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Prevalent as an acquired abnormality in cancer, the role of tumor protein p53 (TP53) as a germline mutation continues to evolve. The clinical impact of a germline TP53 mutation is often dramatic and affects the full life course, with a propensity to develop rare tumors in childhood and multiple common cancers of unexpectedly early onset in adulthood. In this article, we review the clinical relevance of germline mutations in the TP53 tumor suppressor gene to current healthcare practice, including the optimal ways to identify patients with Li-Fraumeni syndrome (LFS), to recognize the core cancers associated with LFS, and to develop strategies for early detection of LFS-associated tumors. Several TP53-targeted approaches to improve outcomes in LFS patients are also reviewed. A case report is used to highlight special TP53 testing dilemmas and unique challenges associated with genetic testing decisions in the current age of rapidly advancing genomic technologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 4×
“TP53 is the most frequently mutated gene in human cancer [19], with the prevalence of acquired TP53 mutations being highest in epithelial ovarian cancers (47 %), colorectal cancers (43 %), head/neck cancers (42 %), and esophageal cancers (41 %) [International Agency for Research on Cancer (IARC) database, R15 release]…”
InfluentialWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 1×
“Missense mutations are usually transcriptionally inactive; however, some reports have shown gain-of-function oncogenic effects in TP53 [79, 80].”
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Hainaut, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.367 · Cited by 375 · cited 2×
“Using the active metabolite of benzo[a]pyrene (a byproduct of cigarette smoke), Pfeifer’s group induced TP53 mutagenesis, causing malignant transformation with unique genetic alterations [35, 36].”
Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors
Varley, J. M., McGown, G., Thorncroft, M., James, L. A., Margison, G. P., Forster, G., Evans, D. G. R., Harris, M., Kelsey, A. M., & Birch, J. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302575 · Cited by 266
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230 · cited 1×
“The Chompret criteria were most recently updated in 2009 to better identify families with milder phenotypes [84, 91].”
Latronico, A. C., Pinto, E. M., Domenice, S., Fragoso, M. C. B. V., Martin, R. M., Zerbini, M. C., Lucon, A. M., & Mendonca, B. B. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7957 · Cited by 224
Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation
Figueiredo, B. C., Sandrini, R., Zambetti, G. P., Pereira, R. M., Cheng, C., Liu, W., Lacerda, L., Pianovski, M. A., Michalkiewicz, E., Jenkins, J., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2004.030551 · Cited by 166
Garritano, S., Gemignani, F., Palmero, E. I., Olivier, M., Martel-Planche, G., Le Calvez-Kelm, F., Brugiéres, L., Vargas, F. R., Brentani, R. R., Ashton-Prolla, P., et al. (2010) · Human Mutation · doi:10.1002/humu.21151 · Cited by 153 · cited 2×
“The R337H mutation is present at a high frequency in southern Brazil (about 1 in 300 individuals) [67, 68], and evidence shows it to be a founder mutation [52, 69].”
Pinto, E. M., Billerbeck, A. E. C., Villares, M. C. B. F., Domenice, S., Mendonça, B. B., & Latronico, A. C. (2004) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302004000500009 · Cited by 153 · cited 1×
“The R337H mutation is present at a high frequency in southern Brazil (about 1 in 300 individuals) [67, 68], and evidence shows it to be a founder mutation [52, 69].”
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.
Bishop, M. R., Iversen, P. L., Bayever, E., Sharp, J. G., Greiner, T. C., Copple, B. L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1320 · Cited by 136
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations: Table 1
Wilson, J. R. F., Bateman, A. C., Hanson, H., An, Q., Evans, G., Rahman, N., Jones, J. L., & Eccles, D. M. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2010.078113 · Cited by 122 · cited 1×
“TP53 mutation carriers from a UK regional genetics service [58] 9 NA 83”
TP53 Germline Mutations in Adult Patients with Adrenocortical Carcinoma
Herrmann, L. J. M., Heinze, B., Fassnacht, M., Willenberg, H. S., Quinkler, M., Reisch, N., Zink, M., Allolio, B., & Hahner, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1982 · Cited by 109
Cited by
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
“High-stringency structural variants were further required to have at least four supporting read pairs with a minimum mapping quality of 20 and were restricted to somatic structural variant sizes from 300 bp to 500 Mb. Copy-number calling.”
Li-Fraumeni syndrome: cancer risk assessment and clinical management
McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 281
Hendrickson, P. G., Luo, Y., Kohlmann, W., Schiffman, J., Maese, L., Bishop, A. J., Lloyd, S., Kokeny, K. E., Hitchcock, Y. J., Poppe, M. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3427 · Cited by 64
Connecting Malfunctioning Glial Cells and Brain Degenerative Disorders
Kaminsky, N., Bihari, O., Kanner, S., & Barzilai, A. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.04.003 · Cited by 38
Metadata
- Authors
- Sorrell, A. D., Espenschied, C. R., Culver, J. O., & Weitzel, J. N.
- Venue
- Molecular Diagnosis & Therapy
- Published
- 2013-01-26
- Volume
- 17
- Issue
- 1
- Pages
- 31-47
- ISSN
- 1177-1062 (ISSN-L)
- 1179-2000
- OpenAlex
- W1604076448
- Cited by
- 107
- References
- 22
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.